Clinical evaluation of advanced MALDI-TOF MS for carbapenemase subtyping in Gram-negative isolates

被引:0
|
作者
Cheon, Dong Huey [1 ]
Jang, Heejung [1 ]
Choi, Yoon Kyung [1 ]
Oh, Won Seok [1 ]
Hwang, Seohyun [1 ]
Park, Ju-Ri [1 ]
Kim, Hyojin [1 ]
Park, Yoonha [1 ]
Lee, Saeyoung [1 ]
Yang, Won Suk [1 ]
Kim, Min Jin [2 ]
Lee, Sun Hwa [2 ]
Baek, Je-Hyun [1 ]
机构
[1] Seegene Med Fdn, R&D Ctr Clin Mass Spectrometry, Seoul, South Korea
[2] Seegene Med Fdn, Dept Lab Med, Seoul, South Korea
关键词
carbapenemase-producing Enterobacteriaceae; MALDI-TOF MS; carbapenemase; clinical diagnostics; antibiotics resistance; subtyping; RESISTANT ENTEROBACTERIACEAE; BETA-LACTAMASE; EPIDEMIOLOGY; VARIANTS;
D O I
10.1128/jcm.01475-24
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The spread of carbapenemase-producing Enterobacterales (CPE) is emerging as a significant clinical concern in tertiary hospitals and, in particular, long-term care facilities with deficiencies in infection control. This study aims to evaluate an advanced matrix-assisted laser desorption/ionization (A-MALDI) mass spectrometry method for the identification of carbapenemases and further discrimination of their subtypes in clinical isolates. The A-MALDI method was employed to detect CPE target proteins. Enhancements were made to improve detectability and mass accuracy through the optimization of MALDI-TOF settings and internal mass calibration. A total of 581 clinical isolates were analyzed, including 469 CPE isolates (388 Klebsiella pneumoniae carbapenemases [KPC], 51 NDM, 40 OXA, and 2 GES) and 112 carbapenemase-negative isolates. Clinical evaluation of the A-MALDI demonstrated 100% accuracy and precision in identifying all the collected CPE isolates. Additionally, A-MALDI successfully discriminated individual carbapenemase subtypes (KPC-2 or KPC-3/KPC-4, OXA-48 or OXA-181 or OXA-232, GES-5 or GES-24) and also differentiated co-producing carbapenemase strains (KPC and NDM, KPC and OXA, KPC and GES, and NDM and OXA), attributed to its high mass accuracy and simultaneous detection capability. A-MALDI is considered a valuable diagnostic tool for accurately identifying CPE and carbapenemase's subtypes in clinical isolates. It may also aid in selecting appropriate antibiotics for each carbapenemase subtype. Ultimately, we expect that the A-MALDI method will contribute to preventing the spread of antibiotic resistance and improving human public health. IMPORTANCE A-MALDI clearly demonstrated excellent ability to identify CPEs such as KPC, NDM, OXA, and GES when carbapenemase is present in the strain (100% accuracy and precision). The method also successfully discriminated carbapenemase subtypes and simultaneous detection of co-producing multiple carbapenemases in a single strain. This is the first report for simultaneous and multiple detection of intact carbapenemases of KPC, NDM, OXA, and GES using matrix-assisted laser desorption/ionization mass spectrometry in a clinical isolate.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland
    Brauncajs, Malgorzata
    Bielec, Filip
    Macieja, Anna
    Pastuszak-Lewandoska, Dorota
    BIOMEDICINES, 2023, 11 (07)
  • [42] MALDI-TOF mass spectrometry proteomic based identification of clinical bacterial isolates
    Panda, Ashutosh
    Kurapati, Sravya
    Samantaray, Jyotish C.
    Srinivasan, Alagiri
    Khalil, Shehla
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2014, 140 : 770 - 777
  • [43] Routine use of MALDI-TOF MS for anaerobic bacterial identification in clinical microbiology
    Shannon, Samantha
    Kronemann, Daniel
    Patel, Robin
    Schuetz, Audrey N.
    ANAEROBE, 2018, 54 : 191 - 196
  • [44] Biotyping of Multidrug-Resistant Klebsiella pneumoniae Clinical Isolates from France and Algeria Using MALDI-TOF MS
    Berrazeg, Meryem
    Diene, Seydina M.
    Drissi, Mourad
    Kempf, Marie
    Richet, Herve
    Landraud, Luce
    Rolain, Jean-Marc
    PLOS ONE, 2013, 8 (04):
  • [45] Evaluation of serum carbohydrate-deficient transferrin by HPLC and MALDI-TOF MS
    Sogawa, Kazuyuki
    Iida, Fumie
    Kawshima, Yusuke
    Yamada, Mako
    Satoh, Mamoru
    Sanda, Akihiro
    Takizawa, Hirotaka
    Maruyama, Katsuya
    Wada, Yoshinao
    Nomura, Fumio
    CLINICA CHIMICA ACTA, 2015, 448 : 8 - 12
  • [46] MALDI-TOF MS: A Reliable Tool in the Real Life of the Clinical Microbiology Laboratory
    Calderaro, Adriana
    Chezzi, Carlo
    MICROORGANISMS, 2024, 12 (02)
  • [47] Clinical Validation of a 106-SNV MALDI-ToF MS Pharmacogenomic Panel
    Williams, Grace R.
    Cook, Leanne
    Lewis, Lionel D.
    Tsongalis, Gregory J.
    Nerenz, Robert D.
    JOURNAL OF APPLIED LABORATORY MEDICINE, 2020, 5 (03): : 454 - 466
  • [48] Evaluation of sample preparation protocols for spider venom profiling by MALDI-TOF MS
    Bocanek, Ondrej
    Sedo, Ondrej
    Pekar, Stano
    Zdrahal, Zbynek
    TOXICON, 2017, 133 : 18 - 25
  • [49] Analysis of human blood plasma by MALDI-TOF MS -: Evaluation of critical parameters
    Zschörnig, O
    Richter, V
    Rassoul, F
    Süss, R
    Arnold, K
    Schiller, J
    ANALYTICAL LETTERS, 2006, 39 (06) : 1101 - 1113
  • [50] Evaluation of mass spectrometry: MALDI-TOF MS for fast and reliable yeast identification
    Relloso, Maria S.
    Nievas, Jimena
    Fares Taie, Santiago
    Farquharson, Victoria
    Mujica, Maria T.
    Romano, Vanesa
    Zarate, Mariela S.
    Smayevsky, Jorgelina
    REVISTA ARGENTINA DE MICROBIOLOGIA, 2015, 47 (02): : 103 - 107